BGLAP and neoplasm: Finally, the mouse PC-3 xenografts showed that activation of GPRC6A with osteocalcin enhances primary tumor growth, and that CRISPR/Cas9 induced mutations in GPRC6A in PC-3 cells resulted in reduced primary tumor growth and the further enhancement of tumor growth in response to osteocalcin administration.